True · Brier 0.25

CMS approves a Medicare New Technology Add-On Payment (NTAP) for SAINT Neuromodulation under the inpatient prospective payment system.

TRUE on the effective date of a Medicare inpatient prospective payment system (IPPS) final rule, published in the Federal Register by CMS, that approves a New Technology Add-On Payment for SAINT Neuromodulation. The proposed rule, the open comment period, a coding assignment or a national coverage analysis is not approval. Resolution source: the Federal Register (CMS Medicare IPPS final rule, NTAP determinations). FALSE at the deadline when no IPPS final rule approving an NTAP for SAINT Neuromodulation has been published.

Resolution source: Federal Register (CMS Medicare IPPS final rule, NTAP determinations)

Readings: 'under Medicare, go to a hospital with depression and leave no longer depressed' is read as Medicare paying for SAINT in hospitals through the NTAP program the post names.; '79% of the time' restates the SAINT trial remission rate; it is not a separate scored claim.

upheld (date): I tested whether the date should be the publication date (2023-08-28) or the display date (2023-08-01) rather than the effective date, and whether the approval was final. The FY 2024 IPPS/LTCH PPS final rule (88 FR 58640) states 'we are finalizing that the maximum new technology add-on payment for a case involving the use of the SAINT Neuromodulation System is $12,675.00 for FY 2024', with cases identified by ICD-10-PCS X0Z0X18, and 'DATES: This final rule is effective October 1, 2023.' The criterion names the effective date, so 2023-10-01 is correct. No earlier IPPS rule approved an NTAP for SAINT; FDA clearance came 2022-09-06, after the FY 2023 application cycle. The rule also records the applicant's statement that SAINT would be commercially available on 2024-04-15, which bears on the newness period, not on approval. Occurred on 2023-10-01 stands.